- Home
- BGNE vs MKL Comparison
BGNE vs MKL Comparison
Compare BGNE & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- MKL
- Stock Information
- Founded
- BGNE 2010
- MKL 1930
- Country
- BGNE Cayman Islands
- MKL United States
- Employees
- BGNE N/A
- MKL N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- MKL Property-Casualty Insurers
- Sector
- BGNE Health Care
- MKL Finance
- Exchange
- BGNE Nasdaq
- MKL Nasdaq
- Market Cap
- BGNE 21.0B
- MKL 20.0B
- IPO Year
- BGNE 2016
- MKL 1986
- Fundamental
- Price
- BGNE $189.23
- MKL $1,709.46
- Analyst Decision
- BGNE Buy
- MKL Hold
- Analyst Count
- BGNE 7
- MKL 6
- Target Price
- BGNE $247.07
- MKL $1,662.20
- AVG Volume (30 Days)
- BGNE 281.8K
- MKL 54.9K
- Earning Date
- BGNE 11-12-2024
- MKL 10-30-2024
- Dividend Yield
- BGNE N/A
- MKL N/A
- EPS Growth
- BGNE N/A
- MKL 54.78
- EPS
- BGNE N/A
- MKL 216.91
- Revenue
- BGNE $3,351,304,621.00
- MKL $17,422,281,000.00
- Revenue This Year
- BGNE $969.39
- MKL N/A
- Revenue Next Year
- BGNE $24.79
- MKL N/A
- P/E Ratio
- BGNE N/A
- MKL $7.87
- Revenue Growth
- BGNE 50.22
- MKL 13.34
- 52 Week Low
- BGNE $126.97
- MKL $1,342.66
- 52 Week High
- BGNE $248.16
- MKL $1,729.80
- Technical
- Relative Strength Index (RSI)
- BGNE 31.72
- MKL 75.55
- Support Level
- BGNE $189.60
- MKL $1,650.03
- Resistance Level
- BGNE $209.29
- MKL $1,676.56
- Average True Range (ATR)
- BGNE 6.42
- MKL 32.95
- MACD
- BGNE -2.10
- MKL 13.63
- Stochastic Oscillator
- BGNE 9.19
- MKL 90.25
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little less than 15% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.